Detalhe da pesquisa
1.
Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
Am J Respir Crit Care Med
; 195(9): 1171-1180, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28060545
2.
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Lancet
; 381(9871): 1021-8, 2013 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-23391465
3.
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
Am J Respir Crit Care Med
; 181(12): 1407-17, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20167847
4.
Safety, Pharmacokinetics, and Neutralizing Activity of SYN023, a Mixture of Two Novel Antirabies Monoclonal Antibodies Intended for Use in Postrabies Exposure Prophylaxis.
Clin Pharmacol Drug Dev
; 10(7): 807-817, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33493368
5.
Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
Vaccine
; 39(40): 5822-5830, 2021 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34483020
6.
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.
JCI Insight
; 4(23)2019 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697647
7.
Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.
Lancet Respir Med
; 5(4): 282-290, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28215501
8.
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Vaccine
; 35(12): 1652-1661, 2017 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28216183
9.
Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis.
Vaccine
; 34(21): 2430-2436, 2016 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27026148
10.
T-cell activation is an immune correlate of risk in BCG vaccinated infants.
Nat Commun
; 7: 11290, 2016 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27068708
11.
The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Vaccine
; 33(15): 1890-6, 2015 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25698492
12.
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG.
Tuberculosis (Edinb)
; 93(2): 143-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23410889
13.
A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.
Vaccine
; 30(12): 2098-108, 2012 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22296955
14.
Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.
Nat Commun
; 7: 11633, 2016 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27151680